Background Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to
protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid …

In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …

Background At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish
vaccine-induced protective immune responses, particularly as antibody titers wane over time. …

Omicron Neutralization and mRNA-1273 Boosters Neutralization of the omicron variant was
assessed in serum samples obtained from persons who had received an mRNA-1273 …

Background The incidence of coronavirus disease 2019 (Covid-19) among adolescents
between 12 and 17 years of age was approximately 900 per 100,000 population from April 1 …

The emergence of SARS-CoV-2 variants of concern (VOCs) and variants of interest (VOIs)
with decreased susceptibility to neutralization has generated interest in assessments of …

All current vaccines for COVID-19 utilize ancestral SARS-CoV-2 spike with the goal of
generating protective neutralizing antibodies. The recent emergence and rapid spread of several …

Cross-Reactive Neutralization of SARS-CoV-2 Variants An analysis of cross-reactive viral
binding and neutralization of emerging SARS-CoV-2 variants, modeled with the use of …

Background The safety, reactogenicity, immunogenicity, and efficacy of the mRNA-1273
coronavirus disease 2019 (Covid-19) vaccine in young children are unknown. Methods Part 1 of …